The effect of PAMAM dendrimer concentration, generation size and surface functional group on the aqueous solubility of candesartan cilexetil

References

• Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904–912.
   PubMed Web of Science ®Google Scholar
• Ripley TL, Chonlahan JS, Germany RE. Candesartan in heart failure. Clin Interv Aging 2006;1:357–366.
   PubMed Web of Science ®Google Scholar
• Candesartan [Internet]. c2005–2016. Ottawa: Canadian Institutes of Health Research; [cited 2015 Jan 01]. Available from: http://www.drugbank.ca/drugs/DB00796.
   Google Scholar
• Leibovici M, Kanari I, Fox M. Teva Pharmaceuticals USA Inc., assignee. 2009 Feb 19. Pharmaceutical composition comprising candesartan cilexetil. United States Patent Application Publication US 2009/0048316.
   Google Scholar
• Detroja C, Chavhan S, Sawant K. Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study. Sci Pharm 2011;79:635–651.
   PubMedGoogle Scholar
• Damodharan N, Ghanta N. Preperation and evaluation of solid dispersion of Candesartan cilexetil. J Pharm Res 2012;5:333–337.
   Google Scholar
• Zulal NA, Lakshmi PK. Enhancement of solubility and bioavailability of candesartan cilexetil using natural P-Glycoprotein inhibitors. Trop J Pharm Res 2015;14:21–26.
   Web of Science ®Google Scholar
• Shukla JB, Patel SJ. Formulation and evaluation of self micro emulsifying system of candesartan cilexetil. Int J Pharm Pharm Sci 2010;2:143–146.
   Google Scholar
• Reddy MS, Goud PS, Apte S. Solubility enhancement of candesartan cilexetil by self-emulsifying drug delivery systems. Int J Pharm Sci Res 2012;3:2098–2104.
   Google Scholar
• Maheshwari RK, Chandan C. Mixed solvency concept in reducing surfactant concentration of self-emulsifying drug delivery systems of candesartan cilexetil using D-optimal mixture design. Asian J Pharm 2013;7:83.
   Google Scholar
• Gautama SP, Vermab A. PAMAM dendrimers: novel polymeric nanoarchitectures for solubility enhancement of candesartan cilexetil. Pharmaceut Sci 2012;1:1–4.
   Google Scholar
• Al Omari AA, Al Omari MM, Badwan AA, Al-Sou'od KA. Effect of cyclodextrins on the solubility and stability of candesartan cilexetil in solution and solid state. J Pharmaceut Biomed Anal 2011;54:503–509.
   PubMed Web of Science ®Google Scholar
• Sravya M, Deveswaran R, Bharath S, et al. Development of orodispersible tablets of candesartan cilexetil-β-cyclodextrin complex. J Pharm 2013;2013:1–13.
   Google Scholar
• Raghad AN, Hind EZ. Enhancement of candesartan cilexetil dissolution rate by using different methods. Asian J Pharm Clin Res 2015;8:320–326.
   Google Scholar
• Taghavi Pourianazar N, Mutlu P, Gunduz U. Bioapplications of poly(amidoamine) (PAMAM) dendrimers in nanomedicine. J Nanopart Res 2014;16:1.
   Web of Science ®Google Scholar
• Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev 2012;64:102–115.
   Web of Science ®Google Scholar
• Kalhapure RS, Kathiravan MK, Akamanchi KG, Govender T. Dendrimers – from organic synthesis to pharmaceutical applications: an update. Pharm Dev Technol 2015;20:22–40.
   PubMed Web of Science ®Google Scholar
• Svenson S, Chauhan AS. Dendrimers for enhanced drug solubilization. Nanomedicine (London, England) 2008;3:679–702.
   PubMed Web of Science ®Google Scholar
• Jain NK, Gupta U. Application of dendrimer–drug complexation in the enhancement of drug solubility and bioavailability. Expert Opin Drug Metab Toxicol 2008;4:1035–1052.
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci 2014;39:268–307.
   Web of Science ®Google Scholar
• Cakara D, Kleimann J, Borkovec M. Microscopic protonation equilibria of poly(amidoamine) dendrimers from macroscopic titrations. Macromolecules 2003;36:4201–4207.
   Web of Science ®Google Scholar
• Niu Y, Sun L, Crooks RM. Determination of the intrinsic proton binding constants for poly (amidoamine) dendrimers via potentiometric pH titration. Macromolecules 2003;36:5725–5731.
   Web of Science ®Google Scholar
• Fréchet JMJ, Tomalia DA. Dendrimers and other dendritic polymers. Chichester, UK: Wiley; 2001.
   Google Scholar
• Greish K, Thiagarajan G, Herd H, et al. Size and surface charge significantly influence the toxicity of silica and dendritic nanoparticles. Nanotoxicology 2012;6:713–723.
   PubMed Web of Science ®Google Scholar
• Qingxing X, Chi-Hwa W, Daniel Wayne P. Polymeric carriers for gene delivery: chitosan and poly(amidoamine) dendrimers. Curr Pharm Des 2010;16:2350–2368.
   PubMed Web of Science ®Google Scholar
• Yellepeddi VK, Kumar A, Palakurthi S. Surface modified poly(amido)amine dendrimers as diverse nanomolecules for biomedical applications. Expert Opin Drug Deliv 2009;6:835–850.
   PubMed Web of Science ®Google Scholar
• Jain K, Kesharwani P, Gupta U, Jain NK. Dendrimer toxicity: let's meet the challenge. Int J Pharm 2010;394:122–142.
   PubMed Web of Science ®Google Scholar
• Jevprasesphant R, Penny J, Jalal R, et al. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm 2003;252:263–266.
   PubMed Web of Science ®Google Scholar
• Schulz JD, Gauthier MA, Leroux J-C. Improving oral drug bioavailability with polycations? Eur J Pharm Biopharm 2015;97:427–437.
   PubMed Web of Science ®Google Scholar
• Katare YK, Daya RP, Sookram Gray C, et al. Brain targeting of a water insoluble antipsychotic drug haloperidol via the intranasal route using PAMAM dendrimer. Mol Pharm 2015;12:3380–3388.
   PubMed Web of Science ®Google Scholar
• Karolczak K, Rozalska S, Wieczorek M, et al. Poly(amido)amine dendrimers generation 4.0 (PAMAM G4) reduce blood hyperglycemia and restore impaired blood-brain barrier permeability in streptozotocin diabetes in rats. Int J Pharm 2012;436:508–518.
   PubMed Web of Science ®Google Scholar
• Jędrych M, Borowska K, Galus R, Jodłowska-Jędrych B. The evaluation of the biomedical effectiveness of poly(amido)amine dendrimers generation 4.0 as a drug and as drug carriers: a systematic review and meta-analysis. Int J Pharm 2014;462:38–43.
   PubMed Web of Science ®Google Scholar
• Thiagarajan G, Greish K, Ghandehari H. Charge affects the oral toxicity of poly (amidoamine) dendrimers. Eur J Pharm Biopharm 2013;84:330–334.
   PubMed Web of Science ®Google Scholar
• Ionov M, Gardikis K, Wrobel D, et al. Interaction of cationic phosphorus dendrimers (CPD) with charged and neutral lipid membranes. Colloids Surf B Biointerfaces 2011;82:8–12.
   PubMed Web of Science ®Google Scholar
• Tiriveedhi V, Kitchens KM, Nevels KJ, et al. Kinetic analysis of the interaction between poly(amidoamine) dendrimers and model lipid membranes. Biochim Biophys Acta 2011;1808:209–218.
   PubMed Web of Science ®Google Scholar
• Gupta U, Agashe HB, Asthana A, Jain N. Dendrimers: novel polymeric nanoarchitectures for solubility enhancement. Biomacromolecules 2006;7:649–658.
   PubMed Web of Science ®Google Scholar
• Boas U, Heegaard PMH. Dendrimers in drug research. Chem Soc Rev 2004;33:43–63.
   PubMed Web of Science ®Google Scholar
• Hawker CJ, Wooley KL, Frechet JMJ. Unimolecular micelles and globular amphiphiles: dendritic macromolecules as novel recyclable solubilization agents. J Chem Soc, Perkin Trans 1 1993;1287–1297.
   Google Scholar
• Newkome GR, Moorefield CN, Baker GR, et al. Unimolecular micelles. Angew Chem Int Ed Engl 1991;30:1178–1180.
   Web of Science ®Google Scholar
• Yiyun C, Tongwen X. Dendrimers as potential drug carriers. Part I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers. Eur J Med Chem 2005;40:1188–1192.
   PubMed Web of Science ®Google Scholar
• Chauhan AS, Sridevi S, Chalasani KB, et al. Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin. J Control Release 2003;90:335–343.
   PubMed Web of Science ®Google Scholar
• Devarakonda B, Hill RA, Liebenberg W, et al. Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins. Int J Pharm 2005;304:193–209.
   PubMed Web of Science ®Google Scholar
• Beezer AE, King ASH, Martin IK, et al. Dendrimers as potential drug carriers; encapsulation of acidic hydrophobes within water soluble PAMAM derivatives. Tetrahedron 2003;59:3873–3880.
   Web of Science ®Google Scholar
• Svenson S, Chouhan A, Reyna L, Tomalia D. Solubility enhancement of poorly water soluble molecules using dendrimers. Mater Matters 2007;2:24–26.
   Google Scholar
• Malik N, Wiwattanapatapee R, Klopsch R, et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release 2000;65:133–148.
   PubMed Web of Science ®Google Scholar
• Bodewein L, Schmelter F, D Fiore S, et al. Differences in toxicity of anionic and cationic PAMAM and PPI dendrimers in zebrafish embryos and cancer cell lines. Toxicol Appl Pharmacol 2016;305:83–92.
   PubMed Web of Science ®Google Scholar
• Morgan MT, Carnahan MA, Immoos CE, et al. Dendritic Molecular Capsules for Hydrophobic Compounds. J Am Chem Soc 2003;125:15485–15489.
   PubMed Web of Science ®Google Scholar
• Gu L, Wu Z, Qi X, et al. Polyamidomine dendrimers: an excellent drug carrier for improving the solubility and bioavailability of puerarin. Pharmaceut Dev Technol 2013;18:1051–1057.
   PubMed Web of Science ®Google Scholar
• Ertürk AS, Tülü M, Bozdoğan AE, Parali T. Microwave assisted synthesis of Jeffamine cored PAMAM dendrimers. Eur Polym J 2014;52:218–226.
   Web of Science ®Google Scholar
• Erturk AS, Gurbuz MU, Tulu M, Bozdogan AE. Water-soluble TRIS-terminated PAMAM dendrimers: microwave-assisted synthesis, characterization and Cu(ii) intradendrimer complexes. RSC Advances 2015;5:60581–60595.
   Web of Science ®Google Scholar
• Yin R, Zhu Y, Tomalia D, Ibuki H. Architectural copolymers: rod-shaped, cylindrical dendrimers. J Am Chem Soc 1998;120:2678–2679.
   Web of Science ®Google Scholar
• Ozturk K, Erturk AS, Sarisozen C, et al. Cytotoxicity and in vitro characterization studies of synthesized Jeffamine-cored PAMAM dendrimers. J Microencapsul 2014;31: 127–136.
   PubMed Web of Science ®Google Scholar
• Devarakonda B, Otto DP, Judefeind A, et al. Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes. Int J Pharm 2007;345:142–153.
   PubMed Web of Science ®Google Scholar
• Kleinman MH, Flory JH, Tomalia DA, Turro NJ. Effect of protonation and PAMAM dendrimer size on the complexation and dynamic mobility of 2-naphthol. J Phys Chem B 2000;104:11472–11479.
   Web of Science ®Google Scholar
• Kolhe P, Misra E, Kannan RM, et al. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm 2003;259:143–160.
   PubMed Web of Science ®Google Scholar
• Higuchi T, Connors KA. Phase-solubility techniques. Advan Anal Chem Instr 1965;4:117–212.
   Google Scholar
• De Muth JE. Basic statistics and pharmaceutical statistical applications. Boca Raton, Florida: CRC Press; 2014.
   Google Scholar
• Esfand R, Tomalia DA. Laboratory synthesis of poly(amidoamine)(PAMAM) dendrimers. Dendrimers and other dendritic polymers. Chichester, UK: John Wiley & Sons, Ltd; 2002:587–604.
   Google Scholar
• Esfand R, Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today 2001;6:427–436.
   PubMed Web of Science ®Google Scholar
• Pistolis G, Malliaris A, Tsiourvas D, Paleos CM. Poly (propyleneimine) dendrimers as pH-sensitive controlled-release systems. Chemistry-Weinhheim. Eur J 1999;5: 1440–1444.
   Google Scholar
• Stuart B. Infrared spectroscopy. Wiley Online Library; 2005.
   Google Scholar
• Popescu M-C, Filip D, Vasile C, et al. Characterization by Fourier transform infrared spectroscopy (FT-IR) and 2D IR correlation spectroscopy of PAMAM dendrimer. J Phys Chem B 2006;110:14198–14211.
   PubMed Web of Science ®Google Scholar
• Singh P, Gupta U, Asthana A, Jain NK. Folate and folate − PEG − PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug Chem 2008;19:2239–2252.
   PubMed Web of Science ®Google Scholar
• Mishra M. Handbook of encapsulation and controlled release. Boca Raton, Florida: CRC Press; 2015.
   Google Scholar
• Matsunaga H, Eguchi T, Nishijima K, et al. Solid-state characterization of candesartan cilexetil (TCV-116): crystal structure and molecular mobility. Chem Pharma Bull 1999;47:182–186.
   Web of Science ®Google Scholar
• Kamalakkannan V, Puratchikody A, Ramanathan L. Development and characterization of controlled release polar lipid microparticles of candesartan cilexetil by solid dispersion. Res Pharma Sci 2013;8:125–136.
   PubMedGoogle Scholar
• Naylor AM, Goddard Iii WA, Kiefer GE, Tomalia DA. Starburst dendrimers. 5. Molecular shape control. J Am Chem Soc 1989;111:2339–2341.
   Web of Science ®Google Scholar
• Devarakonda B, Hill R, Devilliers M. The effect of PAMAM dendrimer generation size and surface functional group on the aqueous solubility of nifedipine. Int J Pharm 2004;284:133–140.
   PubMed Web of Science ®Google Scholar
• Ballauff M, Likos CN. Dendrimers in solution: insight from theory and simulation. Angew Chem Int Ed Engl 2004;43:2998–3020.
   PubMed Web of Science ®Google Scholar
• Baars MWPL, Meijer EW. Host-guest chemistry of dendritic molecules. In: Vögtle F, ed. Dendrimers II: architecture, nanostructure and supramolecular chemistry. Berlin, Heidelberg: Springer Berlin Heidelberg; 2000:1311–1182.
   Google Scholar
• Chauhan AS, Jain NK, Diwan PV, Khopade AJ. Solubility enhancement of indomethacin with poly(amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats. J Drug Target 2004;12:575–583.
   PubMed Web of Science ®Google Scholar
• Gowardhane AP, Kadam NV, Dutta S. Review on enhancement of solubilization process. Am J Drug Dis Dev 2014;4:134–152.
   Google Scholar